



Sheet 1 of 1

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: <b>OC01626K</b>	APPLICATION NO.: <b>10/666,424</b>
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT: <b>Kamil Paruch et al.</b>	
(Use several sheets if necessary)		FILING DATE: <b>9/19/2003</b>	GROUP:

### U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	NO
	AL	EP 0 778 277	06/11/1997	EPO				
	AM	WO 02/06286	01/24/2002	PCT				
	AN	WO 88/04298	06/16/1988	PCT				
	AO							
	AP							

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AQ	Vesely et al., "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", <i>Eur. J. Biochem</i> (1994), 224: 771-785.
AR	Senderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms", <i>Journal of Clinical Oncology</i> (September 1998), 16(9): 2986-2999.
AS	Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5", <i>Eur. J. Biochem.</i> (1997), 243: 527-536.
AT	Bible et al., "Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration", <i>Cancer Research</i> (August 15, 1997), 57: 3375-3380.
AU	Shiota et al., "Synthesis and Structure- Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5-a]pyrimidine Derivatives", <i>Chem. Pharm. Bull.</i> (1999), 47(7): 928-938.
AV	Yasuo Makisumi, "Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5-a]pyrimidines", <i>Chem. Pharm. Bull.</i> (1962), 10: 620-626.

EXAMINER  DATE CONSIDERED **3/7/06**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 1 of 2

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: <b>OC01626K</b>	APPLICATION NO.: <b>10/666,424</b>
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT: <b>Kamil Paruch et al.</b>	
(Use several sheets if necessary)		FILING DATE: <b>09/19/2003</b>	GROUP:

#### U. S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

#### FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
						YES      NO
AL	WO 2002 060492 A	08/08/2002	WIPO			
AM						
AN						
AO						
AP						

#### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AQ	
AR	
AS	
AT	
AU	
AV	

EXAMINER	DATE CONSIDERED
	3/7/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 2 of 2

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: <b>OC01626K</b>	APPLICATION NO.: <b>10/666,424</b>
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT: <b>Kamil Paruch et al.</b>	
(Use several sheets if necessary)		FILING DATE: <b>09/19/2003</b>	GROUP:

#### U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
AW						
AX						
AY						
AZ						
BA						
BB						
BC						
BD						
BE						
BF						
BG						

#### FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
						YES NO
BH	WO 02/10162	02/07/2002	WIPO			
BI						
BJ						
BK						
BL						

#### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BM	A. Sanderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms", <i>J. Clin. Oncology</i> , <b>16</b> : 2986-2999 (1998).
BN	J. Vesely et al., "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", <i>Eur. J. Biochem.</i> , <b>224</b> : 771-786 (1994).
BO	I. Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases cdc2, cdk2 and cdk5", <i>Eur. J. Biochem.</i> , <b>243</b> : 527-536 (1997).
BP	K. S. Kim et al., "Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities", <i>J. Medicinal Chemistry</i> , <b>45</b> : 3905-3927 (2002)
BQ	
BR	

EXAMINER	<i>J. V. M.</i>	DATE CONSIDERED	<i>3/7/06</i>
----------	-----------------	-----------------	---------------

\*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.